Literature DB >> 30538123

Type III Hyperlipoproteinemia: The Forgotten, Disregarded, Neglected, Overlooked, Ignored but Highly Atherogenic, and Highly Treatable Dyslipoproteinemia.

Allan D Sniderman1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30538123     DOI: 10.1373/clinchem.2018.298026

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  3 in total

Review 1.  Apolipoprotein E and Atherosclerosis.

Authors:  A D Marais
Journal:  Curr Atheroscler Rep       Date:  2021-05-10       Impact factor: 5.113

2.  Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia).

Authors:  Vincent A Pallazola; Vasanth Sathiyakumar; Jihwan Park; Rachit M Vakil; Peter P Toth; Mariana Lazo-Elizondo; Emily Brown; Renato Quispe; Eliseo Guallar; Maciej Banach; Roger S Blumenthal; Steven R Jones; David Marais; Daniel Soffer; Allan D Sniderman; Seth S Martin
Journal:  Arch Med Sci       Date:  2019-08-02       Impact factor: 3.318

3.  Sex differences in systemic metabolites at four life stages: cohort study with repeated metabolomics.

Authors:  Joshua A Bell; Diana L Santos Ferreira; Abigail Fraser; Ana Luiza G Soares; Laura D Howe; Deborah A Lawlor; David Carslake; George Davey Smith; Linda M O'Keeffe
Journal:  BMC Med       Date:  2021-02-24       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.